Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Slutsky is a top 100 analyst with an average return of 43.2% and a 51.21% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Abivax SA Sponsored ADR, and Palvella Therapeutics.
Olema Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $39.75.
Based on Olema Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $53.09 million. In comparison, last year the company had a GAAP net loss of $30.39 million
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OLMA in relation to earlier this year. Most recently, in March 2026, Shawnte Mitchell, the CLO of OLMA sold 40,000.00 shares for a total of $951,502.52.
